Targeting of the β6 gene to suppress degradation of ECM via inactivation of the MAPK pathway in breast adenocarcinoma cells

Zhang,Yuhua; Wei,Lijing; Yu,Jin; Li,Guang; Zhang,Xiuru; Wang,Anliu; He,Yanjiao; Li,Hongli; Yin,Deling

doi:10.3892/or.2014.3419

Targeting of the β6 gene to suppress degradation of ECM via inactivation of the MAPK pathway in breast adenocarcinoma cells

Authors:
- Yuhua Zhang
- Lijing Wei
- Jin Yu
- Guang Li
- Xiuru Zhang
- Anliu Wang
- Yanjiao He
- Hongli Li
- Deling Yin
View Affiliations

Affiliations: Department of Pathology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, P.R. China, Department of Urology, Shandong Provincial Hospital, Jinan, Shandong 250021, P.R. China, Department of Internal Medicine, Department of Pharmacology, James H. Quillen College of Medicine, East Tennessee State University, Johnson City, TN 37614, USA
Published online on: August 20, 2014 https://doi.org/10.3892/or.2014.3419
Pages: 1787-1795
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Integrin ανβ6 has emerged as a potential novel target for anticancer and plays a major role in promoting malignant tumor progression. Recent studies indicate that integrin ανβ6 occurs in many cancers. However, whether and how ανβ6 is regulated by genetic and epigenetic mechanisms in breast cancer remain unknown. In the present study, two different short hairpin RNAs (shRNAs) targeting the β6 gene were designed and constructed into pSUPER, respectively, which were transfected into the MCF-7 human breast adenocarcinoma cell line. The β6-shRNA stably transfected cells were successfully established, and significant lower levels of ανβ6 mRNA and protein expression were confirmed. Furthermore, inhibition of integrin ανβ6 markedly downregulated the expression of matrix metalloproteinase-9 (MMP-9), matrix metalloproteinase-3 (MMP-3) and urokinase plasminogen activator (uPA) in tumor conditioned medium. Furthermore, β6-shRNA-mediated silencing of the ανβ6 gene obviously decreased the expression of ERK1/2. In particular, supression of integrin ανβ6 caused significant downregulation of the degradation of basement membrane type IV collagen secretion via modulation of the plasminogen activation cascade. Our results thus indicate that ανβ6 plays a fundamental role in promoting invasion and growth of breast adenocarcinoma cells. Taken together, this study revealed that targeting of the β6 gene by RNA interference (RNAi) could efficiently downregulate ανβ6 expression and suppress the ERK1/2-dependent extracellular matrix degradation in vitro, which is dependent upon inactivation of the mitogen-activated protein kinase (MAPK) pathway. These findings may offer a useful therapeutic approach to block invasion and migration of breast cancer cells.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2	Liotta LA and Stetler-Stevenson WG: Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res. 51:S5054–S5059. 1991.PubMed/NCBI
3	Yoon WH, Jung YJ, Kim TD, Li G, Park BJ, Kim JY, Lee YC, Kim JM, Park JI, Park HD, No ZS, Lim K, Hwang BD and Kim YS: Gabexate mesilate inhibits colon cancer growth, invasion, and metastasis by reducing matrix metalloproteinases and angiogenesis. Clin Cancer Res. 10:4517–4526. 2004. View Article : Google Scholar : PubMed/NCBI
4	McGowan PM and Duffy MJ: Matrix metalloproteinase expression and outcome in patients with breast cancer: analysis of a published database. Ann Oncol. 19:1566–1572. 2008. View Article : Google Scholar : PubMed/NCBI
5	Blasi F and Carmeliet P: uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol. 3:932–943. 2002. View Article : Google Scholar : PubMed/NCBI
6	Bates RC, Bellovin DI, Brown C, Maynard E, Wu B, Kawakatsu H, Sheppard D, Oettgen P and Mercurio AM: Transcriptional activation of integrin beta6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. J Clin Invest. 115:339–347. 2005. View Article : Google Scholar
7	Breuss JM, Gallo J, De Lisser HM, Klimanskaya IV, Folkesson HG, Pittet JF, Nishimura SL, Aldape K, Landers DV and Carpenter W: Expression of the beta 6 integrin in development, neoplasia and tissue repair suggests a role in epithelial remodelling. J Cell Sci. 108:2241–2251. 1995.PubMed/NCBI
8	Niu J, Gu X, Ahmed N, Andrews S, Turton J, Bates R and Agrez M: The alphaVbeta6 integrin regulates its own expression with cell crowding: Implications for tumour progression. Int J Cancer. 1:40–48. 2001. View Article : Google Scholar : PubMed/NCBI
9	Arihiro K, Kaneko M, Fujii S, Inai K and Yokosaki Y: Significance of alpha 9 beta 1 and alpha v beta 6 integrin expression in breast carcinoma. Breast Cancer. 7:19–26. 2000. View Article : Google Scholar : PubMed/NCBI
10	Azare J, Leslie K, Al-Ahmadie H, Gerald W, Weinreb PH, Violette SM and Bromberg J: Constitutively activated Stat3 induces tumorigenesis and enhances cell motility of prostate epithelial cells through integrin beta 6. Mol Cell Biol. 27:4444–4453. 2007. View Article : Google Scholar
11	Hausner SH, Abbey CK, Bold RJ, Gagnon MK, Marik J, Marshall JF, Stanecki CE and Sutcliffe JL: Targeted in vivo imaging of integrin alphavbeta6 with an improved radiotracer and its relevance in a pancreatic tumor model. Cancer Res. 69:5843–5850. 2009. View Article : Google Scholar : PubMed/NCBI
12	Hazelbag S, Kenter GG, Gorter A, Dreef EJ, Koopman LA, Violette SM, Weinreb PH and Fleuren GJ: Overexpression of the alpha v beta 6 integrin in cervical squamous cell carcinoma is a prognostic factor for decreased survival. J Pathol. 212:316–324. 2007. View Article : Google Scholar : PubMed/NCBI
13	Eberlein C, Kendrew J, McDaid K, Alfred A, Kang JS, Jacobs VN, Ross SJ, Rooney C, Smith NR, Rinkenberger J, Cao A, Churchman A, Marshall JF, Weir HM, Bedian V, Blakey DC, Foltz IN and Barry ST: A human monoclonal antibody 264RAD targeting αvβ6 integrin reduces tumour growth and metastasis, and modulates key biomarkers in vivo. Oncogene. 32:4406–4416. 2013.
14	Allen MD, Thomas GJ, Clark SE, Dawoud MM, Vallath S, Payne SJ, Gomm JJ, Dreger SA, Dickinson S, Edwards DR, Pennington CJ, Sestak I, Cuzick J, Marshall JF, Hart IR and Jones JL: Altered microenvironment promotes progression of pre-invasive breast cancer: myoepithelial expression of αvβ6 integrin in DCIS identifies high-risk patients and predicts recurrence. Clin Cancer Res. 20:344–357. 2014.PubMed/NCBI
15	Kundu P, Mukhopadhyay AK, Patra R, Banerjee A, Berg DE and Swarnakar S: Cag pathogenicity island-independent up-regulation of matrix metalloproteinases-9 and -2 secretion and expression in mice by Helicobacter pylori infection. J Biol Chem. 281:34651–34662. 2006. View Article : Google Scholar : PubMed/NCBI
16	Niu J, Dorahy DJ, Gu X, Scott RJ, Draganic B, Ahmed N and Agrez MV: Integrin expression in colon cancer cells is regulated by the cytoplasmic domain of the beta6 integrin subunit. Int J Cancer. 99:529–537. 2002. View Article : Google Scholar : PubMed/NCBI
17	Agrez M, Gu X, Turton J, Meldrum C, Niu J, Antalis T and Howard EW: The alpha v beta 6 integrin induces gelatinase B secretion in colon cancer cells. Int J Cancer. 81:90–97. 1999. View Article : Google Scholar : PubMed/NCBI
18	Kähäri VM and Saarialho-Kere U: Matrix metalloproteinases and their inhibitors in tumour growth and invasion. Ann Med. 31:34–45. 1999.PubMed/NCBI
19	Burkhardt BR, Lyle R, Qian K, Arnold AS, Cheng H, Atkinson MA and Zhang YC: Efficient delivery of siRNA into cytokine-stimulated insulinoma cells silences Fas expression and inhibits Fas-mediated apoptosis. FEBS Lett. 580:553–560. 2006. View Article : Google Scholar
20	Chu CY and Rana TM: Potent RNAi by short RNA triggers. RNA. 14:1714–1719. 2008. View Article : Google Scholar : PubMed/NCBI
21	Mungall BA, Schopman NC, Lambeth LS and Doran TJ: Inhibition of Henipavirus infection by RNA interference. Antiviral Res. 80:324–331. 2008. View Article : Google Scholar : PubMed/NCBI
22	Devi GR: siRNA-based approaches in cancer therapy. Cancer Gene Ther. 13:819–829. 2006. View Article : Google Scholar : PubMed/NCBI
23	Delgado R and Regueiro BJ: The future of HIV infection: gene therapy and RNA interference. Enferm Infecc Microbiol Clin. 23:76–83. 2005. View Article : Google Scholar
24	Chen Y, Chen H, Hoffmann A, Cool DR, Diz DI, Chappell MC, Chen AF and Morris M: Adenovirus-mediated small-interference RNA for in vivo silencing of angiotensin AT1a receptors in mouse brain. Hypertension. 47:145–146. 2006. View Article : Google Scholar : PubMed/NCBI
25	Matters GL, Harms JF, McGovern CO, Jayakumar C, Crepin K, Smith ZP, Nelson MC, Stock H, Fenn CW, Kaiser J, Kester M and Smith JP: Growth of human pancreatic cancer is inhibited by down-regulation of gastrin gene expression. Pancreas. 38:151–161. 2009. View Article : Google Scholar : PubMed/NCBI
26	Stein U, Walther W, Stege A, Kaszubiak A, Fichtner I and Lage H: Complete in vivo reversal of the multidrug resistance phenotype by jet-injection of anti-MDR1 short hairpin RNA-encoding plasmid DNA. Mol Ther. 16:178–186. 2008. View Article : Google Scholar : PubMed/NCBI
27	Brummelkamp TR, Bernards R and Agami R: A system for stable expression of short interfering RNAs in mammalian cells. Science. 296:550–553. 2002. View Article : Google Scholar : PubMed/NCBI
28	Agrez M, Chen A, Cone RI, Pytela R and Sheppard D: The alpha v beta 6 integrin promotes proliferation of colon carcinoma cells through a unique region of the beta 6 cytoplasmic domain. J Cell Biol. 127:547–556. 1994. View Article : Google Scholar : PubMed/NCBI
29	Cassoni P, Marrocco T, Bussolati B, Allia E, Munaron L, Sapino A and Bussolati G: Oxytocin induces proliferation and migration in immortalized human dermal microvascular endothelial cells and human breast tumor-derived endothelial cells. Mol Cancer Res. 4:351–359. 2006. View Article : Google Scholar
30	Egeblad M and Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2:161–174. 2002. View Article : Google Scholar : PubMed/NCBI
31	Gu X, Niu J, Dorahy DJ, Scott R and Agrez MV: Integrin alpha(v) beta6-associated ERK2 mediates MMP-9 secretion in colon cancer cells. Br J Cancer. 87:348–351. 2002. View Article : Google Scholar : PubMed/NCBI
32	Godier A and Hunt BJ: Plasminogen receptors and their role in the pathogenesis of inflammatory, autoimmune and malignant disease. J Thromb Haemost. 11:26–34. 2013. View Article : Google Scholar : PubMed/NCBI
33	Ahmed N, Oliva K, Wang Y, Quinn M and Rice G: Downregulation of urokinase plasminogen activator receptor expression inhibits Erk signalling with concomitant suppression of invasiveness due to loss of uPAR-beta1 integrin complex in colon cancer cells. Br J Cancer. 89:374–384. 2003. View Article : Google Scholar
34	Zhang W and Liu HT: MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res. 12:9–18. 2002. View Article : Google Scholar : PubMed/NCBI
35	Koul HK, Pal1 M and Koul S: Role of p38 MAP Kinase signal transduction in solid tumors. Genes Cancer. 4:11–12. 2013.PubMed/NCBI
36	Edick MJ, Tesfay L, Lamb LE, Knudsen BS and Miranti CK: Inhibition of integrin-mediated crosstalk with epidermal growth factor receptor/Erk or Src signaling pathways in autophagic prostate epithelial cells induces caspase-independent death. Mol Biol Cell. 18:2481–2490. 2007. View Article : Google Scholar
37	Ahmed N, Niu J, Dorahy DJ, Gu XH, Andrews S, Meldrum CJ, Scott RJ, Baker MS, Macreadie IG and Agrez MV: Direct integrin alphavbeta6-ERK binding: implications for tumour growth. Oncogene. 21:1370–1380. 2002. View Article : Google Scholar : PubMed/NCBI